| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1810316 | B | Inhibition of human ERG by automated patch clamp assay | Homo sapiens | 1 | ALA1806382 | assay format | Scientific Literature | |
| 2. | ALA1810317 | B | Ex vivo receptor occupancy of CXCR3 in rat blood assessed as inhibition of ITAC binding after 1 hr by flow cytometry | Rattus norvegicus | 9 | ALA1806382 | assay format | Scientific Literature | |
| 3. | ALA1810319 | B | Displacement of radiolabeled CXCL11 from human CXCR3 expressed in CHO cells by scintillation proximity assay | Homo sapiens | 52 | ALA1806382 | cell-based format | Scientific Literature | |
| 4. | ALA1810320 | F | Antagonist activity at human CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay | Homo sapiens | 52 | ALA1806382 | cell-based format | Scientific Literature | |
| 5. | ALA1810321 | F | Antagonist activity at mouse CXCR3 expressed in mouse L1.2 cells assessed as inhibition of ITAC-induced calcium mobilization by FLIPR assay | Mus musculus | 34 | ALA1806382 | cell-based format | Scientific Literature | |
| 6. | ALA1810323 | A | Fraction unbound in rat serum | Rattus norvegicus | 3 | ALA1806382 | cell-free format | Scientific Literature | |
| 7. | ALA1810324 | A | Fraction unbound in human serum | Homo sapiens | 3 | ALA1806382 | cell-free format | Scientific Literature | |
| 8. | ALA1810325 | B | Inhibition of serotonin receptor | 1 | ALA1806382 | assay format | Scientific Literature | ||
| 9. | ALA1810326 | B | Inhibition of adrenergic receptor | 1 | ALA1806382 | assay format | Scientific Literature | ||
| 10. | ALA1810327 | B | Inhibition of dopamine receptor | 1 | ALA1806382 | assay format | Scientific Literature | ||
| 11. | ALA1810328 | P | Solubility of the compound at pH 6.8 | 1 | ALA1806382 | small-molecule physicochemical format | Scientific Literature | ||
| 12. | ALA1810329 | A | Total blood clearance in Sprague-Dawley rat at 1 mg/kg, iv and 3 mg/kg, po | Rattus norvegicus | 1 | ALA1806382 | organism-based format | Scientific Literature | |
| 13. | ALA1810330 | A | Apparent volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv and 3 mg/kg, po | Rattus norvegicus | 1 | ALA1806382 | organism-based format | Scientific Literature | |
| 14. | ALA1810331 | A | Terminal half life in Sprague-Dawley rat at 1 mg/kg, iv and 3 mg/kg, po | Rattus norvegicus | 1 | ALA1806382 | organism-based format | Scientific Literature | |
| 15. | ALA1810332 | A | Dose normalized AUC (infinity) in Sprague-Dawley rat at 1 mg/kg, iv | Rattus norvegicus | 1 | ALA1806382 | organism-based format | Scientific Literature | |
| 16. | ALA1810333 | A | Dose normalized AUC (infinity) in Sprague-Dawley rat at 3 mg/kg, po | Rattus norvegicus | 1 | ALA1806382 | organism-based format | Scientific Literature | |
| 17. | ALA1810381 | A | Oral bioavailability in Sprague-Dawley rat at 3 mg/kg | Rattus norvegicus | 1 | ALA1806382 | organism-based format | Scientific Literature | |
| 18. | ALA1810382 | A | Dose normalized Cmax in Sprague-Dawley rat at 3 mg/kg, po | Rattus norvegicus | 1 | ALA1806382 | organism-based format | Scientific Literature | |
| 19. | ALA1810383 | A | Dose normalized Tmax in Sprague-Dawley rat at 3 mg/kg, po | Rattus norvegicus | 1 | ALA1806382 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!